tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Tzakis AG et al. Two-year experience with FK 506 in pediatric patients. 1993 Transplant. Proc. pmid:7679822
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. 1994 Transplant. Proc. pmid:7513476
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Furian L et al. Everolimus associated with low-dose calcineurin inhibitors, an option in kidney transplant recipients of very old donors. 2014 Transplant. Proc. pmid:25498057
Nazmul MN et al. Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report. 2017 Transplant. Proc. pmid:29198681
Wiesner RH Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. 1998 Transplant. Proc. pmid:9636565
Suzuki K et al. Effect of tacrolimus in renal transplant recipients with immunoglobulin-A nephropathy. 2000 Transplant. Proc. pmid:11119910
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Lopes CT et al. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. 2008 Transplant. Proc. pmid:18455036
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Ciancio G et al. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. 1998 Transplant. Proc. pmid:9636624
Bruce DS et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9636625
Fukushima N et al. Role of endothelial apoptosis in delayed xenograft rejection in pig-to-baboon cardiac transplantation. 1999 Transplant. Proc. pmid:10578268
Comuzzi C et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. 2010 Transplant. Proc. pmid:20534291
Moffatt SD and Metcalfe SM FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578271
Amada N et al. Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood. 2005 Transplant. Proc. pmid:15848577
Töz H et al. Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies. 2004 Jan-Feb Transplant. Proc. pmid:15013324
Marchewka Z et al. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers. 2009 Transplant. Proc. pmid:19545703
Kim SJ et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. 2009 Transplant. Proc. pmid:19545705
Sánchez-Lázaro IJ et al. Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. 2010 Transplant. Proc. pmid:20970650
Bachetoni A et al. Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation. 2007 Jul-Aug Transplant. Proc. pmid:17692678
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Woo J et al. Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. 1991 Transplant. Proc. pmid:1721319
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Schumacher G et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. 2002 Transplant. Proc. pmid:12176410
Izuishi K et al. Effect of an immunosuppressive agent, tacroliums (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems of rat liver microsomes. 2003 Transplant. Proc. pmid:12591538
Kindt MV et al. Tacrolimus toxicity in rhesus monkey: model for clinical side effects. 1999 Transplant. Proc. pmid:10616519
Yoshimura N et al. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients. 2005 Transplant. Proc. pmid:15919458
Sugitani A et al. Long-term results of tacrolimus therapy for renal transplantation in patients with diabetic nephropathy in Japan. 2005 Transplant. Proc. pmid:15919459
Hayes D et al. Aerosolized tacrolimus: a case report in a lung transplant recipient. 2010 Transplant. Proc. pmid:21094875
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Nüssler NC et al. CD8+ host cells infiltrate the intestinal mucosa after allogeneic small bowel transplantation even in the absence of acute rejection. 1996 Transplant. Proc. pmid:8907898
Takahashi N et al. Nitric oxide generation in renal allograft recipients. 1998 Transplant. Proc. pmid:9838306
Yoshimura N et al. Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. 1998 Transplant. Proc. pmid:9838372
Chamienia A et al. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. 2006 Jan-Feb Transplant. Proc. pmid:16504670
Gregory CR Immunosuppressive approaches to the prevention of graft vascular disease. 1998 Transplant. Proc. pmid:9595134
Gentil MA et al. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age. 2003 Transplant. Proc. pmid:12962766
Garcia I Efficacy and safety of dual versus triple tacrolimus-based therapy in kidney transplantation: two-year follow-up. 2002 Transplant. Proc. pmid:12176516
Jiang H et al. FK 506 and deoxyspergualin: additive immunosuppressive effect on rat cardiac allograft rejection in vivo and mitogen-stimulated human lymphocyte responses in vitro. 1994 Transplant. Proc. pmid:7520631
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Youbin Z et al. Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Gene Overexpression Prolongs the Survival of Rat Allogeneic Heart Allografts. 2015 Transplant. Proc. pmid:26518962
Burke GW et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. 1997 Feb-Mar Transplant. Proc. pmid:9123275
Ota H et al. Intrathymic microchimerism predicts rejection response in allograft recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123279
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Song Z et al. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. 1999 Feb-Mar Transplant. Proc. pmid:10083437
Navia MA Rational design of new immunosuppressive drugs. 1999 Feb-Mar Transplant. Proc. pmid:10083489
Hsu KH et al. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience. 2010 Transplant. Proc. pmid:20430208
Tsao CI et al. Unplanned readmission within 1 year after heart transplantation in Taiwan. 2010 Transplant. Proc. pmid:20430212
Mohacsi P et al. Immunosuppression in ABO-incompatible transplantation. 2001 Transplant. Proc. pmid:11377508
Artz MA et al. Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels. 2002 Transplant. Proc. pmid:12176579
Jonas S et al. Corticosteroid-free therapy after tacrolimus-based dual immunosuppression versus cyclosporine-based quadruple-induction therapy. 2001 Transplant. Proc. pmid:11377511
Boucher A et al. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. 2002 Transplant. Proc. pmid:12176582
Saber LT et al. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. 2007 Transplant. Proc. pmid:18089330
Chang HR et al. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients. 2007 Transplant. Proc. pmid:18089339
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Chung YW et al. Tacrolimus-Induced Apoptosis is Mediated by Endoplasmic Reticulum-derived Calcium-dependent Caspases-3,-12 in Jurkat Cells. 2018 Transplant. Proc. pmid:29731088
Dudley CR Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267179
Falkenstein K and Dunn S Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. 1998 Transplant. Proc. pmid:9723354
Eun SC et al. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. 2013 Transplant. Proc. pmid:23769045
Liu W et al. Transfusion of endothelial cells with lentivirus-mediated expression of fas ligand prolonged survival of rat liver allograft. 2012 Transplant. Proc. pmid:22664023
Ishida S et al. Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104127
Asensio M et al. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. 2002 Transplant. Proc. pmid:12176650
Matevossian E et al. Nitric oxide inhibition and consecutive Aspisol application show a prolonged survival of orthotopic transplanted livers in a rat model. 2008 Transplant. Proc. pmid:18555092
Kanodia KV et al. Study of acute antibody-mediated rejection in renal allograft biopsies. 2008 Transplant. Proc. pmid:18555123
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Pirenne J et al. Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267396
Langrehr JM et al. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267404
Ribas Y et al. Lack of accommodation after long-term survival of hamster xenografts in rats. 1999 Transplant. Proc. pmid:10500752
Toki K et al. Histopathologic findings in routine biopsies of renal transplant allografts. 1999 Transplant. Proc. pmid:10500759
Müller V et al. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. 1998 Transplant. Proc. pmid:9636396
Silber RE et al. Comparison of the effect of FK 506 and alpha/beta-T-cell antibody R73 on transplant vascular sclerosis after heterotopic rat heart transplantation. 1998 Transplant. Proc. pmid:9636398
Nichelle L et al. Arterial hypertension in renal transplant recipients treated with tacrolimus or cyclosporine-Neoral. 2002 Transplant. Proc. pmid:12431623
Barten MJ et al. Assessment of immunosuppression by lymphocyte functions in human blood. 2002 Transplant. Proc. pmid:12431640
Ciancio G et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. 2010 Transplant. Proc. pmid:21094804
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Teng D et al. Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy. 2006 Transplant. Proc. pmid:16980034
Bing P et al. Comparison of expression of TGF-beta1, its receptors TGFbeta1R-I and TGFbeta1R-II in rat kidneys during chronic nephropathy induced by cyclosporine and tacrolimus. 2006 Transplant. Proc. pmid:16980036
Friemann S et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. 1998 Transplant. Proc. pmid:9636504
Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. 2014 Transplant. Proc. pmid:24656020